Miromatrix drops as FDA puts bioengineered organ trial application on hold

Miromatrix Medical

14/12/2022 23:19

** Shares of Miromatrix Medical Inc  MIRO.O  fall ~15% to
$3.47 after market  
    ** Co says U.S. FDA informed that its application for trial
on experimental bioengineered organ miroliverELAP has been
placed on clinical hold  urn:newsml:reuters.com:*:nGNXb7lCWJ
    ** Says FDA indicated it will provide an official clinical
hold letter to Miromatrix within 30 days; co plans to provide
additional updates pending communication with FDA
    ** Miromatrix had submitted application for trial in
mid-November to FDA
    ** As of last close, stock was down ~13% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))